Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2005
08/03/2005CN1649899A Connective tissue stimulating peptides
08/03/2005CN1649898A Novel peptides and the application thereof in therapy
08/03/2005CN1649897A FALP proteins
08/03/2005CN1649895A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
08/03/2005CN1649893A Dipeptide derivatives having a N-terminal 2-thiocyl group as vasopeptidase inhibitors
08/03/2005CN1649890A Anti-protozoal vaccine
08/03/2005CN1649864A Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
08/03/2005CN1649840A Non-peptidic BRS-3 agonists
08/03/2005CN1649645A Depsipeptide for therapy of kidney cancer
08/03/2005CN1649644A Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions
08/03/2005CN1649627A Methods and conpositions for treating, preventing or delaying onset of a neoplasm
08/03/2005CN1649621A Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
08/03/2005CN1649620A 医疗装置 Medical devices
08/03/2005CN1649619A Method and composition for treating skin wounds with epidermal growth factor
08/03/2005CN1649618A Methods
08/03/2005CN1649617A Remedies for liver diseases, hyperlipemia and diabetes
08/03/2005CN1649615A Pharmaceutical formulations
08/03/2005CN1649612A Induction method for cell differentiation
08/03/2005CN1649596A Treatment of hypertension in women receiving hormone replacement therapy
08/03/2005CN1649567A Composition having gelling properties for the prolonged delivery of bioactive substances
08/03/2005CN1649496A Composition and method to alter lean body mass and bone properties in a subject
08/03/2005CN1648247A Method for producing recombined blood vessel chalone in bacillus coli and its use
08/03/2005CN1648135A Transduction peptide-humanized chloine acetylase fusion protein and its use
08/03/2005CN1648134A Dog intravenous injection albumin, its preparing method and dog intravenous injection albumin preparation
08/03/2005CN1647820A Use of protein kinase Czeta in regulating tumor cell chemotactic movement
08/03/2005CN1647819A Use of active enzyme and composition in preventing and treating gastropathy and cosmetics fields
08/03/2005CN1213070C Monoclonal antibodies directed against the G3BP protein and use
08/03/2005CN1213069C Growth promoting factor and its prepn and use
08/03/2005CN1213068C Improvments in or relating to immune responses to HIV
08/03/2005CN1213067C Sequence number9 bioactive peptide
08/03/2005CN1213066C Sequence number8 bioactive peptide
08/03/2005CN1213065C Bioactive peptide No. 7
08/03/2005CN1213064C Bioactive peptide No. 28
08/03/2005CN1213063C Bioactive peptide No.12
08/03/2005CN1213062C Bioactive peptide No. 13
08/03/2005CN1213061C No.6 bioactive peptide
08/03/2005CN1213060C No. 10 bioactive peptide
08/03/2005CN1213059C Rapid dehydration of proteins
08/03/2005CN1213058C FAP-activated anti-tumor compounds
08/03/2005CN1213057C Structure of antisense oligonucleotide to inhibit activity of telomerase and its application
08/03/2005CN1213036C Novel amide derivatives
08/03/2005CN1212835C Hydroxamate-containing cysteine and serine protease inhibitors
08/03/2005CN1212830C Delivery of solid drug compositions
08/02/2005US6924415 Identified as a target for therapeutic intervention due to its role in molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy
08/02/2005US6924370 Crosslinkable macromers
08/02/2005US6924367 Method of modulating tissue growth using Frzb Protein
08/02/2005US6924358 Protein for use in the treatment and diagnosis of cancer
08/02/2005US6924356 Human protein HHEPU32
08/02/2005US6924355 PRO1343 polypeptides
08/02/2005US6924353 Inhibitors for RNA viruses
08/02/2005US6924311 Measuring blood concentration of high density lipoproteins;medical diagnosis of cardiovasular disorders
08/02/2005US6924292 Nitrogen compounds such as 2-(methylsulfinyl) N [3-(3,4,8,9-tetrahydro-6-methoxy-3,3,8,8-tetramethylfuro[2,3-h]isoquinolin-1-yl)phenyl]acetamide, used as phosphodiesterase inhibitors; antidiabetics; antiinflammatory agents
08/02/2005US6924280 Dipeptide derivatives
08/02/2005US6924268 Method for inactivating gonadotrophs
08/02/2005US6924267 Methods and active substances for protecting organs
08/02/2005US6924266 NTP-peptides and method for removal of tumors
08/02/2005US6924265 Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
08/02/2005US6924264 chain extension of polypeptides using polymers selected from polyethylene glycol, polylactams, albumin, gelatin, acrylic polymers, fatty acids, polysaccharides, lipid and/or dextrans; antidiabetic agents
08/02/2005US6924151 Binding particles; for use in the treatment of blood disorders
08/02/2005US6924141 Inducing the effects of promoted signal transduction with protein and lithium chloride or mimicking via administration of agent that inhibits either catenin phosphorylation or kinase
08/02/2005US6924135 DNA encoding Eimeria glyceroaldehyde-3-phosphate dehydrogenase and uses thereof
08/02/2005US6924128 Packaging cell lines for generation of high titers of recombinant AAV vectors
08/02/2005US6924121 Sperm specific proteins
08/02/2005US6924118 Recombinant intracellular pathogen immunogenic compositions and methods for use
08/02/2005US6924117 Human RRP sequences and methods of use
08/02/2005US6924110 NPHS2 gene involved in the steroid-resistant nephrotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
08/02/2005US6924100 Nucleotide sequences coding preferential polypeptide for use in the treatment and diagnosis of cardiovascular disorders and headaches
08/02/2005US6924096 Includes intact stem loop structures and an antisense nucleic acid; useful for inhibition of selected genes in a cell; allele-specific targeting is also useful in combination replacement gene therapy
08/02/2005US6923988 Solid carrier includes a hydrophililc surfactant and a drug
08/02/2005US6923986 Multiblock biodegradable hydrogels for drug delivery and tissue treatment
08/02/2005US6923981 Fast dissolving orally consumable films
08/02/2005US6923972 Methods for use of genetically modified tumor-targeted bacteria with reduced virulence
08/02/2005US6923968 Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
08/02/2005US6923966 Administering a therapeutically effective amount of a polyoxyethylene glycol modified interferon-alpha to a naive as well as treatment experienced patient having melanoma to increase progression free survival time
08/02/2005US6923965 comprises inhibitors of glycosaminoglycans; for wound healing and angiogenesis
08/02/2005US6923964 amyloid fibrils; for preventing/treating amyloid diseases/Alzheimer's disease
08/02/2005US6923962 Peptide or antibody that competitively inhibits binding of CSP (competence signal peptide) to Streptococcus mutans histidine kinase; endocarditis
08/02/2005US6923961 Chemically activated carboxypolysaccharides and methods for use to inhibit adhesion formation and promote hemostasis
08/02/2005US6923959 Method of pre-inducing a state of immune tolerance before organ transplantation
08/02/2005US6923958 For immunizing a mammal against cancer cells that present a carcinoembryonic antigen (CEA)
08/02/2005US6923957 Inactivated virulence genes
08/02/2005US6923956 Liquid interferon-β formulations
08/02/2005US6923955 Prophylaxis and/or reversing presbyopia by applying localized energy to area to be treated and administering biologically acceptable chemical substance capable of breaking chemical bonds such as disulfide bonds between cortical lens fibers
08/02/2005CA2486833C Solid dosage form comprising desmopressin and method for manufacturing thereof
08/02/2005CA2175670C Process for producing a virus-inactivated factor viii-containing fraction by chromatographic methods
08/02/2005CA2170020C Retroviral protease inhibiting compounds
08/02/2005CA2169297C Protein- or peptide-cochleate vaccines and methods of immunizing using the same
08/02/2005CA2118121C Methods and compositions for the treatment of diseases with interferon while reducing side effects
08/02/2005CA2078539C Process for producing humanized chimera antibody
07/2005
07/30/2005CA2495048A1 Hemostatic compositions and devices
07/30/2005CA2456593A1 Peptides for the diagnosis, monitoring and treatment of diabetes
07/29/2005CA2493655A1 Transglutaminase has intrinsic kinase activity
07/28/2005WO2005069010A1 Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 4 (mglur4)
07/28/2005WO2005069009A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN STEROID PROGESTIN RECEPTOR BETA (mSR-BETA)
07/28/2005WO2005068999A1 Diagnostics and therapeutics for diseases associated with human progestin receptor gamma (mpr-gamma)
07/28/2005WO2005068998A1 Diagnostics and therapeutics for diseases associated with human progestin receptor aplha (msr-alpha)
07/28/2005WO2005068663A2 Methods of using peroxisome proliferator-activated receptor alpha target genes
07/28/2005WO2005068641A1 Integrase fusion proteins and their use with integrating gene therapy
07/28/2005WO2005068633A1 Differentiation regulating agent containing gene which regulating differentiation from stem cells into natural killer cells as effective ingredient
07/28/2005WO2005068632A1 EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME
1 ... 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 ... 3163